Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations and analyst consensus. We help you understand fair value estimates and potential upside or downside scenarios for any stock you are considering. Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections based on Wall Street research.
Pharvaris N.V. Ordinary Shares (PHVS), a clinical-stage biotech company focused on rare disease therapies, traded at $28.56 as of 2026-04-02, marking a 3.02% decline during recent trading activity. No recently released earnings data is available for PHVS at the time of writing. This analysis breaks down prevailing market context, key technical support and resistance levels, and potential near-term scenarios for market participants to monitor, without making any directional forecasts or investmen
What are bullish arguments for Pharvaris N.V. (PHVS) Stock | Price at $28.56, Down 3.02% - Undervalued Stocks
PHVS - Stock Analysis
4370 Comments
731 Likes
1
Anaysha
Influential Reader
2 hours ago
I really needed this yesterday, not today.
👍 64
Reply
2
Edlynn
Loyal User
5 hours ago
Am I the only one seeing this?
👍 89
Reply
3
Tj
Regular Reader
1 day ago
This came just a little too late.
👍 61
Reply
4
Lynaya
Returning User
1 day ago
Who else is thinking deeper about this?
👍 236
Reply
5
Zymani
Loyal User
2 days ago
That made me do a double-take. 👀
👍 108
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.